Tuesday - March 10, 2026

Category Archives: Professional Services

Advanced Cervical Cancer Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the Advanced Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical … Continue reading →

Esophageal Cancer Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Oncolys BioPharma Inc, Genentech, OncoTherapy Science, Shionogi, CStone Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Acute Lymphocytic Leukemia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Cellectis S.A, Autolus Limited, Takara Bio, AbbVies, Janssen LLC

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Lymphocytic Leukemia pipeline constitutes 120+ key companies continuously working towards developing 125+ Acute Lymphocytic Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Tiefenbacher Group’s “Amifampridine” Market size expansion of Several Folds by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Amifampridine (Tiefenbacher Group’s) providing insights into the drug market landscape and market forecast of Amifampridine upto 2034. The report, titled “Amifampridine Sales … Continue reading →